Furthermore, considering the estimated Risk Ratio (1.51), UHRF1 gene overexpression in TCC patients increases the risk of poor outcome for 51% in the 2-year evaluation period, compared to TCC subgroup with normal gene expression levels. This evidence concerns the gene UHRF1 and tarsal-carpal coalition syndrome.